c="alpha 2 chain" 1:5 1:7||t="test"||cui="C1414557"||tot="FCGRT gene"||ns="-913"
c="osteogenesis imperfecta type III" 1:14 1:17||t="problem"||cui="C0268362"||tot="Osteogenesis imperfecta type III"||ns="-1000"
c="general, osteogenesis imperfecta" 2:1 2:3||t="problem"||cui="C0029434"||tot="Osteogenesis Imperfecta"||ns="-901"
c="brittle bone disease" 2:4 2:6||t="problem"||cui="C0029434"||tot="Osteogenesis Imperfecta"||ns="-1000"
c="alpha 2 chains" 2:20 2:22||t="test"||cui="C1414557"||tot="FCGRT gene"||ns="-896"
c="osteogenesis imperfecta" 2:49 2:50||t="problem"||cui="C0029434"||tot="Osteogenesis Imperfecta"||ns="-1000"
c="glycine" 2:103 2:103||t="medication"||cui="C0017890"||tot="Glycine"||ns="-1000"
c="alpha chain" 2:109 2:110||t="test"||cui="C1414557"||tot="FCGRT gene"||ns="-1000"
c="serine" 2:112 2:112||t="medication"||cui="C0036720"||tot="Serine"||ns="-1000"
